Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel G Haller

Showing results (21-30 of 112) with videos related to

Pageof 12
Sort By:
Anti-Cancer Drugs|June 5, 2002
Docetaxel in advanced gastric cancerDaniel G Haller, Jean-Louis Misset
JAMA Oncology|August 5, 2021
Primary Chemoradiotherapy for Older Patients With Esophageal CancerJennifer R Eads, Daniel G Haller
Journal of Oncology Practice|September 22, 2010
Provisional clinical opinionDaniel G Haller, John V Cox
Gastrointestinal Cancer Research : GCR|March 6, 2009
Colorectal cancer treatment in the elderly: tailored therapy approachesAnjali N Avadhani, Daniel G Haller
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2009
Provisional clinical opinionDaniel G Haller, John V Cox
Nature Reviews. Clinical Oncology|April 25, 2009
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancerUrsina R Teitelbaum, Daniel G Haller
Clinical Colorectal Cancer|October 14, 2004
Future directions with angiogenesis inhibitors in colorectal cancerJoshua H Bilenker, Daniel G Haller
Gastrointestinal Cancer Research : GCR|April 9, 2009
Accomplishments in 2007 in the adjuvant treatment of colorectal cancerAimery de Gramont, Daniel G Haller
Gastrointestinal Cancer Research : GCR|April 9, 2009
Accomplishments in gastrointestinal oncology in 2007: conclusionAimery de Gramont, Daniel G Haller
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Bevacizumab beyond progression: does this make sense?Lee M Ellis, Daniel G Haller
Pageof 12

Showing results (21-30 of 112) with videos related to

Sort By:
Pageof 12
Anti-Cancer Drugs|June 5, 2002
Docetaxel in advanced gastric cancerDaniel G Haller, Jean-Louis Misset
JAMA Oncology|August 5, 2021
Primary Chemoradiotherapy for Older Patients With Esophageal CancerJennifer R Eads, Daniel G Haller
Journal of Oncology Practice|September 22, 2010
Provisional clinical opinionDaniel G Haller, John V Cox
Gastrointestinal Cancer Research : GCR|March 6, 2009
Colorectal cancer treatment in the elderly: tailored therapy approachesAnjali N Avadhani, Daniel G Haller
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2009
Provisional clinical opinionDaniel G Haller, John V Cox
Nature Reviews. Clinical Oncology|April 25, 2009
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancerUrsina R Teitelbaum, Daniel G Haller
Clinical Colorectal Cancer|October 14, 2004
Future directions with angiogenesis inhibitors in colorectal cancerJoshua H Bilenker, Daniel G Haller
Gastrointestinal Cancer Research : GCR|April 9, 2009
Accomplishments in 2007 in the adjuvant treatment of colorectal cancerAimery de Gramont, Daniel G Haller
Gastrointestinal Cancer Research : GCR|April 9, 2009
Accomplishments in gastrointestinal oncology in 2007: conclusionAimery de Gramont, Daniel G Haller
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Bevacizumab beyond progression: does this make sense?Lee M Ellis, Daniel G Haller
Pageof 12